- Home
- TNXP vs SSSS Comparison
TNXP vs SSSS Comparison
Compare TNXP & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- SSSS
- Stock Information
- Founded
- TNXP 2007
- SSSS 2010
- Country
- TNXP United States
- SSSS United States
- Employees
- TNXP N/A
- SSSS N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- TNXP Health Care
- SSSS Finance
- Exchange
- TNXP Nasdaq
- SSSS Nasdaq
- Market Cap
- TNXP 118.2M
- SSSS 107.7M
- IPO Year
- TNXP N/A
- SSSS N/A
- Fundamental
- Price
- TNXP $18.83
- SSSS $5.27
- Analyst Decision
- TNXP Strong Buy
- SSSS Buy
- Analyst Count
- TNXP 2
- SSSS 2
- Target Price
- TNXP $585.00
- SSSS $8.00
- AVG Volume (30 Days)
- TNXP 573.9K
- SSSS 81.1K
- Earning Date
- TNXP 05-20-2025
- SSSS 05-06-2025
- Dividend Yield
- TNXP N/A
- SSSS N/A
- EPS Growth
- TNXP N/A
- SSSS N/A
- EPS
- TNXP N/A
- SSSS N/A
- Revenue
- TNXP $10,094,000.00
- SSSS $3,644,430.00
- Revenue This Year
- TNXP $12.17
- SSSS $6.95
- Revenue Next Year
- TNXP $789.15
- SSSS N/A
- P/E Ratio
- TNXP N/A
- SSSS N/A
- Revenue Growth
- TNXP 29.94
- SSSS N/A
- 52 Week Low
- TNXP $6.76
- SSSS $3.52
- 52 Week High
- TNXP $672.00
- SSSS $6.83
- Technical
- Relative Strength Index (RSI)
- TNXP 53.35
- SSSS 59.92
- Support Level
- TNXP $18.55
- SSSS $5.05
- Resistance Level
- TNXP $21.99
- SSSS $5.41
- Average True Range (ATR)
- TNXP 1.53
- SSSS 0.23
- MACD
- TNXP 0.22
- SSSS 0.11
- Stochastic Oscillator
- TNXP 58.64
- SSSS 86.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.